Hanna, G. J., Gupta, T. R., Trippa, L., Rettig, E. M., Margalit, D. N., Tishler, R. B., Pashtan, I., Kim, E., Droznin, A., Gunasti, L., Maddox, R., Minken, J., Mukundan, D., Sehgal, K., Dennis, M. J., O’Connor, T., Qian, J. M., Boyd, G. H., Saraf, A., Gil, D. M., Sethi, R. K., Annino, D. J., Goguen, L. A., Guenette, J. P., Bakhtiar, M., Jo, V. Y., Wong, K., Uppaluri, R., Haddad, R. I., Schoenfeld, J. D. (2026). Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial. Nature Communications. https://doi.org/10.1038/s41467-026-72984-7